APA (7th ed.) Citation

Gomes, F., Gilding, N., Tan, V., Christoforou, K., Rule, J., Aziez, A., . . . Minchom, A. (2024). 101 Real-world analysis of the impact of pemetrexed in first-line maintenance (1LM) with immunotherapy (IO) for non-squamous (NSQ) advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking targetable mutations, prior to and during the COVID-19 pandemic. Lung Cancer (01695002), 190, N.PAG. https://doi.org/10.1016/j.lungcan.2024.107662

Chicago Style (17th ed.) Citation

Gomes, Fabio, Niall Gilding, Vivian Tan, Katerina Christoforou, Joanne Rule, Amine Aziez, Adam Januszewski, and Anna Minchom. "101 Real-world Analysis of the Impact of Pemetrexed in First-line Maintenance (1LM) with Immunotherapy (IO) for Non-squamous (NSQ) Advanced/metastatic Non-small Cell Lung Cancer (a/mNSCLC) Lacking Targetable Mutations, Prior to and During the COVID-19 Pandemic." Lung Cancer (01695002) 190 (2024): N.PAG. https://doi.org/10.1016/j.lungcan.2024.107662.

MLA (9th ed.) Citation

Gomes, Fabio, et al. "101 Real-world Analysis of the Impact of Pemetrexed in First-line Maintenance (1LM) with Immunotherapy (IO) for Non-squamous (NSQ) Advanced/metastatic Non-small Cell Lung Cancer (a/mNSCLC) Lacking Targetable Mutations, Prior to and During the COVID-19 Pandemic." Lung Cancer (01695002), vol. 190, 2024, p. N.PAG, https://doi.org/10.1016/j.lungcan.2024.107662.